Biogen Reports final analysis Data for Tildrakizumab in Acute kidney injury

Biogen today announced final analysis results for Tildrakizumab in patients with Acute kidney injury. The study demonstrated that Tildrakizumab demonstrates superior efficacy vs standard of care compared to standard of care or placebo. These results provide important insights into the treatment of Acute kidney injury and support the continued development of Tildrakizumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Tildrakizumab was consistent with previous observations, with no new safety signals identified.